Primary chemotherapy in locally advanced breast cancer: Comparative trial of two regimens with dose intensification
DOI:
https://doi.org/10.32635/2176-9745.RBC.1998v44n1.2796Keywords:
Locally Advanced Breast Cancer, Primary Chemotherapy, Dose IntensificationAbstract
A prospective clinicai trial, phase III, multicentric, open, comparative and randomized, was performed. Sixty patient swith locally advanced breast câncer, stage IIIA, were divided in two groups and submitted to primary chemotherapy, with and without intensification of doses, for 4 cycles and surgery. It has been used regiinen FEC 50 in arm A (5-FU 500 mg/m2 epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2) and FEC 100 in arm B (5-FU 500 mg/m2 epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2). It has been cyclically analyzed: the performance status, weight change, hair loss, digestive and hematologic disorders and cardiotoxicity. After the primary chemotherapy, the clinical objective response rate and pathological response in the surgical specimens were evaluated. The clinicai response (complete + partial response) was 93% in arm A and 96% in arm B. There was a higher proportion of complete responses in arm B. The residual tumor was analyzed in the surgical specimens. In arm A there were 4 (13%) complete pathological responses, 12 (40%) microscopic residual tumor and 14 (47%) macroscopic. In arm B there were 10 (33%) complete pathological responses, 7 (23%) microscopic residual tumor and 13 (44%) macroscopic. It has been concluded that the primary chemotherapy with intensification of doses promoted higher clinicai objective and pathological response rates. The toxicity, reversible and tolerable, was more intense in the arm of high doses.
Downloads
References
Allen, A. -The cardiotoxicity of chemotherapeutic drugs.SeminOncol, 19:529-42,1992.
American Câncer Society - Câncer facts and figures - 1996. Atlanta, American Câncer Society, 1996.
Bland, K.I. (ed) - Management strategies for the care of ad vanced primary and metastatic breast câncer. W. B. Saunders Company. Surg Oncol Clin North Am., Vol 4, No. 4, October 1995.
Bonadonna, G.; Valagussa, P.; Brambilla, C. et alii - Response to primary chemotherapy increases rates of breast preservation and correlates with prognosis (abstract 230). Proc. Am Soc Clin Oncol, 13:107,1994.
Brasil - Ministério da Saúde. Instituto Nacional de Câncer. Pro-Onco. Estimativa da incidência e mortalidade por câncer no Brasil. Rio de Janeiro. Pro-Onco, 1996,13 p.
Buzdar, A.U.; Marsha, D.M.; Hortobagyi, G.N. et alii - Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer? Cancer, 65: 394-9,1990. DOI: https://doi.org/10.1002/1097-0142(19900201)65:3<394::AID-CNCR2820650303>3.0.CO;2-2
Calais, G.; Berger, C.; Descamps, P.; Chavet, S. et alii. - Conservative treatment feasibility with induction chemotherapy, surgery and radiotherapy for patients with breast carcinoma larger than 3cm. Cancer,74(4): 1283-8,1994. DOI: https://doi.org/10.1002/1097-0142(19940815)74:4<1283::AID-CNCR2820740417>3.0.CO;2-S
Carter, S.K. - Principies of cancer therapy. New York: McGraw-HillBook, 1982.
Feldman, L.D.; Hortobagyi, G.N.; Buzdar, A.U.; Frederick, A. et alii.- Pathological assessment of response to induction chemotherapy in breastcancer. Cancer Res, 46: 2578-81, 1986.
Fisher, B. - The evolution of paradigms for the management of breast câncer. A personal perspective. Câncer Res, 52:2371,1992.
Fracchia, A.A.; Evans, J.F.; Einsenberg, B .L. - Stage III carcinoma of the breast. A detailed analysis. Ann Surg, 192:705-10,1980. DOI: https://doi.org/10.1097/00000658-198012000-00002
Magalhães Costa, M.; Novais Dias, E.; Salvador Silva, H. M.; Figueira, A. - Câncer de mama para ginecologistas. Rio de Janeiro, Revinter. 1994.
Freitas Jr., R.; Paulinelli, R.; Queiroz, G.; Jorge, E.A.; Ribeiro, L.F. et alii. - Avaliação da resposta do câncer de mama localmente avançado em pacientes submetidas à quimioterapia neoadjuvante. Rev Bras Mastol, 6(3): 119-25,1996.
Ganzina, F.; Di Pietro, N.; Magni, Q. – Clinical toxicity of 4-epi-doxorubicin (epirubicin). Tumori,71:233-40,1985. DOI: https://doi.org/10.1177/030089168507100304
Gilles,R.; Guinebretière, J.M.;Toussaint, C.; Spielman,M.etalii.-Locally advanced breast cancer contrat enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology, 191(3): 633-8,1994. DOI: https://doi.org/10.1148/radiology.191.3.8184039
Homesley, H.D.; Flarry, D.S.; Hoogstraten, B.; Franklin, E. W. - Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. AmJ Clin Oncol, 15:129-34,1992. DOI: https://doi.org/10.1097/00000421-199204000-00007
Hortobagyi, G.N. - Comprehensive management of locally advanced breast câncer. Cancer,66: 1387-91,1990. DOI: https://doi.org/10.1002/1097-0142(19900915)66:14+<1387::AID-CNCR2820661414>3.0.CO;2-I
Hortobagyi, G.N. - Multidisciplinary management of advanced primary and metastatic breast câncer. Câncer, 74(Suppl. 1): 416-23, 1994. DOI: https://doi.org/10.1002/cncr.2820741329
Hryniuk, W.M.; Bush, H. - The importance of dose intensity in chemotherapy of metastatic breast câncer. J Clin Oncol, 2:1281-7,1984. DOI: https://doi.org/10.1200/JCO.1984.2.11.1281
Italian Multicentre Breast Study With Epirubicin. Phase III randomized study of fluorcuracil, epirubicin, and cyclophosphamide V. fluorouracil, doxorubicin and cy-clophosphamide in advanced breast câncer: Italian multicentre trial. JClin Oncol, 6:976-82,1988. DOI: https://doi.org/10.1200/JCO.1988.6.6.976
Jacquillat, C.; Weil, M.; Auclerc, G. et alii. - Níoadjuvant chemotherapy in the conservative management of breast câncer. A study of 205 patients, In SALMON, S.E. (ed) Adjuvant therapy of câncer V. Orlando, Grune & Stratton, 1987, p 403-409.
Koscielny, S., Tubiana, M., Le Mg. etalii. - Breast cancers: Relationship between the size of the primary tumor and the probability of metastaticdissemination. Br JCancer, 49: 709-15,1984. DOI: https://doi.org/10.1038/bjc.1984.112
Magalhães Costa, M.; Novais Dias, E.; Salvador Silva, H. M.; Figueira, A. - Câncer de mama para ginecologistas. Rio de Janeiro, Revinter. 1994.
Magalhães Costa, M. - Quimioterapia primária em câncer de mama localmente avançado. Tese de Doutorado defendida no IG- UFRJ em maio de 1997.
Marschner, N.; Kreienberg, R.; Souchon, U.; Eggeling, R.; Voigtman, K.; Kaplan, E.; Nagel, G. - Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metas tatic breast câncer: ínterim analysis of a prospective randomized trial.Semin Oncol, 21( 1 Suppl.l): 10-16,1994.
McCready, D.R.; Hortobagyi, G.N.; Kau, S. W.et alii. - The prognostic significance of lymphnode metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg, 124:21-5,1989. DOI: https://doi.org/10.1001/archsurg.1989.01410010027005
Minow, R.A.; Benjamin, R.S.; Gottlieb, J. A. - Adriamycin cardiomyopathy - OverView with determination of risk factors. Câncer ChemotherRep, 6:195-201,1975.
Morrow, M.; Braveman, A.; Thalmo, W. et alii. - Multimodal therapy for locally advanced breast cancer. Arch. Surg., 121:1291-6,1986. DOI: https://doi.org/10.1001/archsurg.121.11.1291
Moskovic, E.C.; Mansi, J.L.; King, D.M.; Murch, C.R.; Smith, I.E. – Mammography in the assessment of response to medical treatment of large primary breast câncer. Clin.Radiol., 47(5): 339-44,1985. DOI: https://doi.org/10.1016/S0009-9260(05)81451-5
Murad, A.; Katz, A. - Oncologia: bases clínicas do tratamento. Rio de Janeiro, Guanabara Koogan, 1996.
Nielsen, D.,Hansen, O.P. -Dombernowsky. Epirubicin cardiac toxicity in patients with advanced breast câncer. Abstract no. 437. AnnOncol3(Suppl.5): 114,1992.
Registro Hospitalar de Câncer: Dados do Hospital do Câncer do INCA: Pro-Onco, l“-ed, 1991.
Shanta, V.; Krishnamurthi, S. – Preoperative multimodal therapy for locally advanced non-
Inflammatory breast cancer. ClinOn-coI, 3(3): 137-40,1991. DOI: https://doi.org/10.1016/S0936-6555(05)80833-7
Yeatman, T.J.; Bland, K.I. - Staging of breast cancer. /«:Blank, K.I.,Copeland,E.M.(eds). The Breast. Philadelphia, W.B. Saunders, 1991, p313-30.
Valagussa, P.; Zambetti, M.; Bonadonna, G. - Prognostic factors in locally advanced noninflammatory breast câncer. Long term results following primary chemotherapy. Breast Cancer ResTreat, 15: 137,1990. DOI: https://doi.org/10.1007/BF01806351
Young, C. W. - Clinicai toxicity of epirubicin. In: Cuna, G.R. (ed). Advances in Clinical Oncology. EDIMES - ITALY. 1989.
